{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T08:14:48Z","timestamp":1788077688024,"version":"build-2784847793"},"reference-count":17,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>Background: The incidence of ischemic cerebrovascular disease (ICVD) among the elderly in Guangxi is higher than the national average. The Zhuang ethnic group, the dominant ethnic group in the region, has unique genetic backgrounds and medication habits, often taking antiplatelet drugs and digestive system medications simultaneously, increasing the risk of drug interactions. Objectives: To explore combined medication characteristics and optimize regimens for elderly ICVD patients in Guangxi, focusing on ethnic genetic differences and drug interactions. Methods: A retrospective analysis included 2135 elderly ICVD patients (873 Zhuang, 1262 Han) from 2019\u20132022; 807 patients received a prospective stratified regimen (2023). CYP2C19 genotypes, platelet function, and clinical outcomes were analyzed. Results: Zhuang patients had a higher CYP2C19*3 allele frequency (28.7% vs 19.2%, P=0.004) and clopidogrel resistance rate (34.1% vs 14.7%, P&lt;0.001). The aspirin +clopidogrel +omeprazole regimen (51.3% usage) increased stroke recurrence risk (HR=2.81). The stratified regimen boosted efficacy to 89.2%, reduced severe bleeding by 57.3%, and lowered 6-month recurrence rate from 15.7% to 8.3% (all P&lt;0.01). Conclusion: Elderly Zhuang ICVD patients show distinct CYP2C19 genotypes associated with clopidogrel resistance. A genotype-liver\/kidney function stratified regimen improves efficacy and safety, supporting precision medication in ethnic minority areas.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.9.246.1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T07:17:16Z","timestamp":1782631036000},"source":"Crossref","is-referenced-by-count":0,"title":["Research on drug interactions and efficacy optimization of combined medication for elderly patients with ischemic cerebrovascular disease in Guangxi Zhuang Autonomous Region"],"prefix":"10.36721","author":[{"given":"Jiaguan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Talihati Z, Maihemuti N, Nuer M, Khan N, Abudurousuli K, Dilimulati D, Nueraihemaiti N, Moore N, Wumaier A and Zhou W (2023). Quince extract resists atherosclerosis in rats by down-regulating the EGFR\/PI3K\/Akt\/GSK-3\u03b2 pathway. Biomed. Pharmacother., 160: 114330-114330.","DOI":"10.1016\/j.biopha.2023.114330"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Avram R, Byrne J, So D, Iturriaga E, Lennon R, Murthy V, Geller N, Goodman S, Rihal C, Rosenberg Y, Bailey K, Farkouh M, Bell M, Cagin C, Chavez I, ElHajjar M, Ginete W, Lerman A, Levisay J, Marzo K, Nazif T, Tanguay J, Pletcher M, Marcus Gregory M, Pereira Naveen L and Olgin J (2023). Digital tool-assisted hospitalization detection in the tailored antiplatelet initiation to lessen outcomes due to decreased clopidogrel response after percutaneous coronary intervention study compared to traditional site-coordinator ascertainment: Intervention study. J. Med. Inter. Res., 25: e47475.","DOI":"10.2196\/47475"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Capranzano P and Angiolillo Dominick J (2021). Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention. Expert. Rev. Cardiovasc. Ther., 9(06): 519-535.","DOI":"10.1080\/14779072.2021.1920925"},{"key":"ref3","unstructured":"Danqing X, Xia D, Qingqing L, Qiong Y, Xueying L and Ying X (2023). Analysis of metabolic status and cardiovascular risk factors in Yao patients with type 2 diabetes in Guangxi. Modern. Prev. Med., 50(06): 975-980."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gerritsen Jasper KW, Zwarthoed Rosa H, Kilgallon John L, Nawabi Noah L, Jessurun Charissa AC, Versyck G, Pruijn Koen P, Fisher Fleur L, Larivi\u00e8re E, Solie L, Mekary Rania A, Satoer Djaina D, Schouten Joost W, Bos Eelke M, Kloet A, Nandoe Tewarie R, Smith Timothy R, Dirven Clemens MF, De Vleeschouwer S, Broekman Marike LD and Vincent Arnaud JPE (2022). Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): A propensity score-matched analysis of an international, multicentre, cohort study. Lance.t Oncol., 23(6): 802-817.","DOI":"10.1016\/S1470-2045(22)00213-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hongzhou G, Zhishuai Y and Rongchong H (2021). Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: A systematic review and meta-analysis. Front. Pharmacol., 12: 694698-694698.","DOI":"10.3389\/fphar.2021.694698"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Jacob JG, George T, Hafeez Ul Hassan V, Umair K, Hani J, Yochai B, Carl JL, Dirk S, Glenn NL and Chayakrit K (2025). Pharmaceutical and clinical implications of proton pump inhibitors with dual antiplatelet therapies: A systematic review.NPJ. Gut. Liver., 2(1): 2-2.","DOI":"10.1038\/s44355-024-00012-w"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"JunMei T, Shuiqing Q, Danyu L,Yefa G, ShiJie T, Qiong Y, Jiawei Y and Chao Z (2024). Evaluation of CYP2C19 genetic variant and its lack of association with valproic acid plasma concentrations among Zhuang and Han schizophrenia patients in Guangxi. Pharmacogen. Pers. Med., 7: 225-236.","DOI":"10.2147\/PGPM.S457805"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Kazuto T, Takuto N, Yosuke M, Ryotaro S, Yu A, Tomoko T, Tatsushi N, Hidetaka M, Masahiro Oi, Hiroyuki S and Yasunari N (2025). Influence of antiplatelet drugs on gastric ulcer healing after endoscopic submucosal dissection in patients with early gastric cancer. DEN. Open., 5(1): e70070.","DOI":"10.1002\/deo2.70070"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ki Young H, Sejung H, Joo Young N, Kyung Sang Y, In Jin J, Jae Yong C and Seonghae Y (2024). Estimation of the benefit from pre-emptive genotyping based on the nationwide cohort data in South Korea. Clin. Transl. Sci., 17(03): e13772-e13772.","DOI":"10.1111\/cts.13772"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Lange-Maia Brittney S, Dugan Sheila A, Crane Melissa M, Williams Joselyn L, Epting Rev. Steve M and Lynch Elizabeth B (2021). Physical function in midlife and older adults from an African American church-based health screening. Am. J. Prev. Med., 60(6): 845-849","DOI":"10.1016\/j.amepre.2020.12.017"},{"key":"ref11","unstructured":"Lima JJ, Thomas CD and Barbarino J (2021). Clinical pharmacogenetics implementation consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Therapy. Clin. Pharmacol. Ther., 11(01): 41-48."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Pengfei L, Mengying C, Ling L, Chen L, Shuang L and Youbin W (2024). Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology. BMC. Pharmacol.  Toxicol., 25(01): 34-34.","DOI":"10.1186\/s40360-024-00750-w"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Que Tran N, Khanh Nguyen B, Tung Pham D, Hang Pham Thi L, Van Anh Nguyen T and Thang Nguyen D (2022). Frequency and distribution of HLA-DQB1 alleles from 2076 cord blood samples of the Vietnamese cohort. Int. J. Immunogenet., 49(5): 340-344.","DOI":"10.1111\/iji.12592"},{"key":"ref14","unstructured":"Ravindra Reddy G, Sayed A Mahmud, Anura M, Ghadeer S, Hala AA, Adoum Oumar A and Sondos T N (2024). Comparative efficacy and safety of novel antiplatelets and standard therapy in patients with coronary artery disease. Cureus., 16(10): e71333."},{"key":"ref15","unstructured":"Shengshou H and Zengwu W (2023). Overview of \"China cardiovascular health and disease report 2022\". Chin. J. Cardiovasc. Res., 21(07): 577-600."},{"key":"ref16","unstructured":"Yinyin C, Qiyang P, Jian L, Xiaofang Z, Xuecun L, Lan H, Chen C, Quming Z, Lu Z, Feng W, Shuna S, Yixiang L, Guoying H and Fang L (2024). Relationship between clopidogrel resistance and genetic variability in Kawasaki disease children with coronary artery lesions. Chin. J. Pediatrics., 62(10): 981-988."}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T07:35:40Z","timestamp":1788075340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.pjps.pk\/single-article?id=7851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":17,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.9.246.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}